BioAlliance Pharma http://http://www.bioalliancepharma.com/eng 01 February 2012 - To gain a better understanding of the company, its product portfolio and its management team, BioAlliance Pharma organizes a symposium "Oncology: key issues for the future" http://http://www.bioalliancepharma.com/eng/content/download/11512/134902/version/1/file/120201EN_SaveTheDate_Journée RD.pdf 26 January 2012 - 2011 achievements and 2012 prospects - BioAlliance Pharma confirms the dynamics of its core business http://http://www.bioalliancepharma.com/eng/content/download/11466/134331/version/1/file/120126EN_CA 2011.pdf 23 January 2012 - BioAlliance Pharma announces two key steps with its AMEP™ biotherapy for metastatic melanoma http://http://www.bioalliancepharma.com/eng/content/download/11428/133860/version/1/file/120123EN_Amep.pdf 04 January 2012 - BioAlliance Pharma: New achievements in the collaboration with its strategic European partner, Therabel http://http://www.bioalliancepharma.com/eng/content/download/11236/131611/version/1/file/120104EN_MilestoneTherabel.pdf 18 November 2011 - BioAlliance Pharma ranked as France's fastest growing company in the 2011 « Deloitte Technology Fast 50 » http://http://www.bioalliancepharma.com/eng/content/download/10916/127876/version/1/file/111118EN_ Deloitte.pdf 14 November 2011 - BioAlliance Pharma reports its consolidated turnover for Q3 and announces progress for Loramyc® commercialization in Italy http://http://www.bioalliancepharma.com/eng/content/download/10887/127522/version/1/file/111114EN_CAQ3.pdf 02 November 2011 - BioAlliance Pharma announces: Grant of « orphan designation » for clonidine Lauriad™ in Europe http://http://www.bioalliancepharma.com/eng/content/download/10780/126199/version/1/file/111102EN_Clonidine obtention Statut orphelin.pdf 05 October 2011 - A major step forward in the development of Sitavir®: European registration file submission for the treatment of recurrent orofacial herpes http://http://www.bioalliancepharma.com/eng/content/download/10521/122890/version/1/file/111005EN_Sitavir EU.pdf 21 September 2011 - Consolidated accounts for the first semester of 2011 and recent significant key events http://http://www.bioalliancepharma.com/eng/content/download/10422/121661/version/1/file/110921EN_Comptes semestriels 2011.pdf 13 September 2011 - BioAlliance Pharma announces positive preliminary phase I clinical results with its AMEP® biotherapy for metastatic melanoma http://http://www.bioalliancepharma.com/eng/content/download/10338/120801/version/1/file/110913EN_AMEP.pdf 12 September 2011 - BioAlliance Pharma announces participation in the Midcap Event on September 22 and 23, 2011 http://http://www.bioalliancepharma.com/eng/content/download/10325/120655/version/1/file/110912EN_Midcap Event.pdf 07 September 2011 - BioAlliance Pharma announces 2 key decisions: Green light granted from French agency for Livatag® Phase III; Full US rights regained for Oravig® http://http://www.bioalliancepharma.com/eng/content/download/10289/120210/version/1/file/110907EN_Oravig Livatag.pdf 05 September 2011 - Presentation of Livatag® survival results at the international liver cancer congress in Hong Kong http://http://www.bioalliancepharma.com/eng/content/download/10275/120051/version/1/file/110905EN_Congres Livatag.pdf 01 August 2011 - BioAlliance Pharma initiates the clinical batches production of Livatag® (doxorubicin Transdrug™) for its phase III clinical trial http://http://www.bioalliancepharma.com/eng/content/download/10108/118009/version/1/file/110801EN_ProductionLivatag.pdf 28 July 2011 - Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products” http://http://www.bioalliancepharma.com/eng/content/download/10092/117816/version/1/file/110728EN_CA Q2 2011.pdf 26 July 2011 - Successful capital increase for BioAlliance Pharma - Over-subscribed transaction - €16.64 million raised http://http://www.bioalliancepharma.com/eng/content/download/10070/117558/version/1/file/110726EN_Cloture levée de fonds.pdf 13 July 2011 - Two key validation steps achieved by BioAlliance Pharma for its advanced orphan product Livatag® and clonidine Lauriad™ - Validation of Phase III clinical trial application for Livatag® -Validation of « orphan drug » designation application forclonidine L http://http://www.bioalliancepharma.com/eng/content/download/10003/116756/version/1/file/110713EN_LivatagClonidine.pdf 11 July 2011 - BioAlliance strengthens the protection of Livatag® (doxorubicin Transdrug™) with the grant of a European patent http://http://www.bioalliancepharma.com/eng/content/download/9984/116572/version/1/file/110711EN_Protection Livatag.pdf 01 July 2011 - BioAlliance Pharma launches a capital increase for an amount of €16 million with maintenance of preferential subscription rights http://http://www.bioalliancepharma.com/eng/content/download/9882/115404/version/1/file/110701EN_Augmentation de capital.pdf 27 June 2011 - BioAlliance Pharma submits a phase III clinical trial application for Livatag® (doxorubicin Transdrug™) to the French Drug Agency (Afssaps) http://http://www.bioalliancepharma.com/eng/content/download/9857/115102/version/1/file/110627EN_Livatag Essai clinique.pdf